Degarelix

Introduction Overview

Generic Name

degarelix

Brand Name

Firmagon

Dosage Form

subcutaneous injection

Drug Class

Gonadotropin-releasing hormone antagonists; Hormones / antineoplastics

Pharmacokinetics

Absorption:
Degarelix is administered via subcutaneous injection, allowing for direct absorption into systemic circulation without the first-pass metabolism seen in oral drugs. Following administration, degarelix shows rapid absorption, achieving substantial systemic levels almost immediately. Due to its peptide nature, absorption kinetics are influenced by injection site perfusion and local tissue factors. The initial loading dose is designed to provide a rapid and sustained plasma concentration, facilitating prompt suppression of testosterone levels within 24 hours.

Distribution:
As a large peptide molecule, degarelix exhibits a limited volume of distribution, predominantly remaining within the vascular and extracellular compartments. It binds minimally to plasma proteins, which facilitates its interactions with GnRH receptors in the pituitary gland. Tissue distribution is largely confined due to its molecular size and polarity, avoiding extensive penetration into the central nervous system. Clinical studies show consistent distribution profiles without accumulation over repeated dosing.

Metabolism:
Degarelix is metabolized primarily via proteolytic degradation by peptidases and proteases in blood and tissues rather than by cytochrome P450 enzymes. This enzymatic breakdown results in inactive peptide fragments. Due to this metabolic pathway, degarelix has limited potential for significant drug interactions mediated by hepatic metabolic enzymes. This degradation process contributes to its pharmacodynamic duration and is not influenced substantially by hepatic impairment.

Elimination:
The elimination of degarelix occurs predominantly via renal excretion of its peptide fragments following metabolic degradation. The half-life supports a monthly dosing regimen, with steady-state plasma levels achievable after initial loading doses. Renal impairment may moderately affect elimination rates; however, dose adjustments are not routinely required. Degarelix does not accumulate in plasma with repeated monthly dosing due to its clearance profile. Clinical monitoring remains essential to ensure therapeutic efficacy and safety.

Dosage Forms

Available Dosage Forms:
Degarelix is supplied as a sterile injectable solution for subcutaneous administration in two concentration strengths: 40 mg/mL and 20 mg/mL. The drug is presented in prefilled syringes intended for injection around the abdominal area.

Dosages for Adults and Adolescents:
The standard dosing regimen for adult males with advanced prostate cancer begins with an initial loading dose of 240 mg, administered as two subcutaneous injections of 120 mg each (using 40 mg/mL concentration). This loading dose ensures rapid and effective testosterone suppression. Maintenance therapy commences 28 days following the first dose, consisting of a single 80 mg injection (20 mg/mL concentration) every 28 days to sustain testosterone suppression.

Specific Patient Populations:
Degarelix dosing is primarily indicated for adult men with advanced prostate cancer. Safety and efficacy in pediatric patients have not been established, and therefore, use in children is not recommended. While no specific dosage adjustments are universally required for renal or hepatic impairment, clinicians should exercise caution in these populations and monitor therapy closely. Women should not use degarelix, especially during pregnancy or breastfeeding, due to potential harm to the fetus or infant.

Summary of Dosage Forms:
- Prefilled syringe injection, 40 mg/mL (for initial 120 mg injections)
- Prefilled syringe injection, 20 mg/mL (for maintenance 80 mg injections)

Mechanism Of Action

Degarelix operates as a potent gonadotropin-releasing hormone (GnRH) receptor antagonist, exerting its pharmacological effects by directly binding to GnRH receptors in the anterior pituitary gland. This binding competitively inhibits the natural GnRH from activating its receptor, thereby blocking the downstream signaling cascade responsible for gonadotropin secretion.

By preventing the activation of GnRH receptors, degarelix rapidly suppresses luteinizing hormone (LH) and follicle-stimulating hormone (FSH) release from the pituitary. The reduction of LH levels leads to a decrease in the stimulation of Leydig cells within the testes, resulting in a swift and profound decline in testosterone production. This decline is critical because prostate cancer growth is often testosterone-dependent, necessitating effective androgen deprivation therapy.

Unlike GnRH agonists, which initially stimulate the receptor causing a transient surge in testosterone before downregulating receptor activity, degarelix immediately blocks receptor activation, thereby avoiding the clinically problematic flare in testosterone levels. This rapid suppression eliminates the need for anti-androgen co-therapy that is often required when using GnRH agonists.

The sustained receptor blockade afforded by degarelix leads to sustained castrate levels of testosterone, halting the progression of hormone-sensitive prostate tumors. Clinical trials have demonstrated extensive suppression of testosterone within 24 hours, maintaining nearly 98% reduction for the duration of monthly dosing intervals. This biochemical and clinical profile positions degarelix as a direct and effective agent in advanced prostate cancer management.

Pharmacological Actions

Potent antagonist of gonadotropin-releasing hormone (GnRH) receptors in the anterior pituitary.
Rapidly suppresses luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion.
Leads to rapid and sustained reduction in circulating testosterone levels.
Prevents testosterone surge associated with GnRH agonists, avoiding clinical flare.
Inhibits androgen-dependent tumor growth in prostate cancer.
Maintains castrate levels of testosterone with monthly administration.
Reduces prostate-specific antigen (PSA) levels correlating with tumor burden.
Modulates hypothalamic-pituitary-gonadal axis to achieve androgen deprivation.
Does not engage in receptor activation, thus lacks initial hormone stimulation.
Exhibits predictable pharmacodynamics facilitating consistent therapeutic effects.

Therapeutic Or Clinical Uses

Treatment of advanced prostate cancer requiring androgen deprivation therapy.
Management of hormone-sensitive prostate tumors reliant on testosterone for growth.
Rapid testosterone suppression in patients where immediate androgen deprivation is critical.
Alternative to GnRH agonists to avoid testosterone flare phenomena.
Used in patients unsuitable for surgical castration or seeking medical castration.
Adjuvant therapy combined with other modalities in advanced prostate cancer.
Treatment strategy for patients at risk for tumor flare symptoms with GnRH agonists.
Maintaining testosterone suppression in long-term management of prostate cancer.
Potential use in clinical trials exploring hormone-responsive malignancies.

Side Or Adverse Effects

Injection site reactions including pain, redness, swelling, itching, and formation of hard lumps.
Hot flashes commonly reported as a result of androgen deprivation.
Weight gain observed in some patients during therapy.
Abnormal liver function tests indicating hepatic impact.
Potential for QT interval prolongation leading to cardiac arrhythmias.
Rare hypersensitivity reactions presenting as hives, facial swelling, or difficulty breathing.
Dizziness, headache, blurred vision, or palpitations possibly related to cardiovascular effects.
Electrolyte imbalances due to hormonal alterations.
Fatigue and general malaise associated with systemic hormonal changes.
Potential impact on bone mineral density over prolonged use.
Possible effects on fertility and sexual dysfunction.
Risk of cardiovascular events in susceptible patients.
Injection site hematoma or abscess formation in rare instances.
Transient increases in liver enzymes requiring monitoring.
Allergic reactions necessitating immediate medical attention.

Precautions

Assess patients for history of heart problems, including congestive heart failure before initiation.
Screen for personal or family history of Long QT syndrome due to risk of arrhythmias.
Monitor electrolytes regularly, especially potassium, calcium, and magnesium levels.
Avoid use in women who are pregnant or breastfeeding due to potential fetal harm.
Use caution in patients with hepatic or renal impairment; monitor liver and kidney function.
Avoid tight clothing or belts around injection site on dosing days to prevent irritation.
Ensure careful handling of bodily fluids post-injection to prevent exposure to caregivers.
Advise patients to report any signs of allergic reaction promptly.
Regularly monitor testosterone and PSA levels to assess therapeutic response.
Counsel patients about possible hot flashes and metabolic changes.
Monitor cardiac status due to potential QT prolongation.
Consider fertility preservation strategies as degarelix may affect reproductive capacity.
Avoid abrupt discontinuation to prevent hormonal withdrawal symptoms.
Inform patients about correct injection site care to reduce local adverse effects.
Adjust concomitant medications that may affect cardiac conduction or electrolyte balance.

Warnings

Not indicated for use in women; contraindicated in pregnancy and breastfeeding.
May cause serious cardiac adverse effects including QT interval prolongation and arrhythmias.
Risk of allergic or anaphylactoid reactions requiring emergency medical intervention.
Potential for significant hormonal changes affecting metabolic and cardiovascular health.
Avoid use in patients with known hypersensitivity to degarelix or its components.
Exposure to body fluids post-injection can pose risk to caregivers; precautions advised.
Should not be administered to children or adolescents; safety and efficacy not established.
Continuous cardiac monitoring recommended in patients with pre-existing heart conditions.
Missed doses can compromise therapeutic effectiveness; adherence to dosing schedule is critical.
Potential transient worsening of symptoms upon initial administration is less likely than with agonists but possible.
Not to be used concomitantly with agents known to prolong QT interval without specialized monitoring.
Inform patients of the importance of follow-up and laboratory monitoring.
Therapy may impact bone density necessitating bone health evaluation during prolonged use.
Patients should avoid vigorous rubbing or scratching at the injection site to prevent complications.
Caution advised in patients with electrolyte abnormalities to prevent cardiac complications.

Contraindication

Known hypersensitivity or allergy to degarelix or any component of the formulation.
Pregnancy due to potential teratogenic effects and risk of fetal harm.
Breastfeeding women as safety profile is not established and risk to infant unknown.
Women who may become pregnant should not receive degarelix.
Patients with congenital or acquired Long QT syndrome without appropriate cardiac management.
Severe hepatic impairment without careful risk-benefit assessment.
Severe renal impairment if monitoring and dose adjustments are not feasible.
Patients with hypersensitivity to other GnRH analogs may require evaluation before use.
Use in pediatric populations is contraindicated due to lack of safety and effectiveness data.
Patients with known electrolyte imbalances that cannot be corrected prior to therapy initiation.
Simultaneous administration with other testosterone-lowering agents without medical supervision.
Patients with active infections at proposed injection sites.
Uncontrolled cardiovascular disease where QT prolongation risk outweighs benefits.
Use during lactation.
Known hypersensitivity to any peptide-based therapeutics structurally related to degarelix.

Drug Interactions

Concomitant use with other medications that prolong QT interval may increase risk of serious cardiac arrhythmias.
Potential interactions with antiarrhythmic drugs such as amiodarone, sotalol, and quinidine.
Interactions with certain antibiotics including macrolides (e.g., erythromycin) and fluoroquinolones (e.g., levofloxacin).
Caution when used with antipsychotic medications that have QT-prolonging potential.
Possible additive effects with other hormone therapies affecting pituitary or gonadal function.
Interactions with electrolyte-modifying agents such as diuretics can exacerbate electrolyte imbalances.
May alter the metabolism or efficacy of drugs metabolized by hormone-dependent pathways.
No significant cytochrome P450-mediated interactions due to peptide metabolic pathway, but vigilance required.
Interactions with certain antidepressants that affect cardiac conduction.
Careful monitoring if combined with HIV protease inhibitors known to prolong QT interval.
Potential pharmacodynamic interactions with antihypertensives affecting cardiac conduction.
Possible interaction with herbal supplements that influence cardiac rhythm or electrolytes.
Avoid initiation or discontinuation of interacting drugs without prior medical evaluation.
No known interaction with common over-the-counter vitamins; however, disclose all substances to prescriber.
Caregivers handling bodily fluids should avoid concurrent use of gloves contaminated by degarelix unless properly changed.

Preparations Of The Drug

Degarelix is available as a sterile injectable solution in prefilled syringes.
Each syringe contains degarelix at concentrations of either 40 mg/mL or 20 mg/mL.
The 40 mg/mL concentration is utilized for the initial dose, administered as two 120 mg injections.
The 20 mg/mL concentration is used for monthly maintenance dosing of 80 mg per injection.
Prepared for subcutaneous administration in the abdominal area by healthcare professionals.
Vials and syringes are stored refrigerated and protected from light until use.
Single-use syringes prevent contamination and ensure dosing accuracy.
Preparation involves warming the syringe to room temperature before administration to minimize injection discomfort.
Manufactured under sterile conditions to maintain drug integrity and safety.
Disposal of syringes and materials must comply with biohazard waste protocols.
Packaging includes clear labeling of concentration and dosage instructions.
No oral or alternative routes of administration are currently available.
Prefilled syringes facilitate ease of administration and dosing compliance in clinical settings.
Instructions for reconstitution are not needed as the solution is provided ready-to-use.
Patients should be educated on injection site care and signs of local adverse reactions.